Key result
Sugammadex reverses neuromuscular block substantially faster than neostigmine with ~24 anaphylaxis cases per 100,000 exposures.
Why the study?
Although sugammadex reverses aminosteroidal neuromuscular block more quickly and predictably than neostigmine, concerns exist regarding its ability to bind other drugs, its effects on the QT interval and clotting times, and a potentially higher-than-anticipated frequency of hypersensitivity reactions.
What is the safety profile and clinical efficacy of sugammadex compared to neostigmine for the reversal of aminosteroid-induced neuromuscular block?
What is the safety profile and clinical efficacy of sugammadex compared to neostigmine for the reversal of aminosteroid-induced neuromuscular block?
Sugammadex rapidly and predictably reverses aminosteroid neuromuscular blockade with fewer cholinergic side effects and lower bradycardia rates than neostigmine, though clinicians must remain vigilant for rare hypersensitivity reactions and arrhythmias and always use neuromuscular monitoring.
Answers are grounded in this paper and cite their sources.
Supports vigilant anaphylaxis monitoring with sugammadex; leaves open need for prospective trials on net benefit versus neostigmine.
Introduction: Sugammadex is a modified cyclodextrin that is able to reverse neuromuscular block induced by aminosteroidal neuromuscular blocking drugs. Compared to reversal with neostigmine, it reverses neuromuscular block quicker and more predictable and without cholinergic side effects. However, there have been concerns about sugammadex ability to bind other drugs and its effects on QT interval and clotting times. In addition, sugammadex might induce hypersensitivity reactions more frequently than initially anticipated. This review summarizes current evidence with regard to these and other safety aspects of sugammadex.Areas covered: This review provides an overview of the efficacy of sugammadex in various patient populations, evaluates potential interactions with other drugs and discusses adverse effects and reactions that have been reported in the literature.Expert opinion: Sugammadex quickly reverses aminosteroid neuromuscular block with less side effects compared to neostigmine. As such, it has the potential to significantly reduce the incidence of residual neuromuscular block and to improve postoperative pulmonary outcome. Current safety concerns mainly focus on hypersensitivity reactions and cardiac arrhythmias. Although the absolute risk for these events is low, ongoing vigilance and research in this area are needed.
No takes yet. Share an insight, caveat, or question.
Martini et al. (2019) conducted a review in Aminosteroid-induced neuromuscular block. Sugammadex vs. Acetylcholinesterase inhibitors (e.g., neostigmine) was evaluated on Safety and efficacy of neuromuscular block reversal (including hypersensitivity, anaphylaxis, cardiac arrhythmias, QTc interval, and coagulation). Sugammadex reverses moderate to deep neuromuscular block in 1.6-3.3 minutes versus 12.8-48.8 minutes for neostigmine, with an estimated anaphylaxis risk of 24 per 100,000 exposures.
Synapse has enriched 10 related papers. Consider them for comparative context: